Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Rhea-AI Summary
Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on August 12, 2025, at 4:30 PM ET in Boston, MA.
The presentation will be accessible via live webcast and available for replay in the Investors section of biodesix.com under "News & Events".
Positive
- None.
Negative
- None.
News Market Reaction 15 Alerts
On the day this news was published, BDSX gained 29.26%, reflecting a significant positive market reaction. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. The stock closed at $0.50 on that trading session. This price movement added approximately $16M to the company's valuation, bringing the market cap to $69M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
Canaccord Genuity 45th Annual Growth Conference
Fireside Chat Date: Tuesday, August 12, 2025
Fireside Chat Time: 4:30 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
Chris.Brinzey@icrhealthcare.com
1-339-970-2843
FAQ
When is Biodesix (BDSX) presenting at the Canaccord Genuity Growth Conference?
Who will represent Biodesix (BDSX) at the Canaccord Conference?
How can investors access Biodesix's Canaccord Conference presentation?
What type of meetings will Biodesix (BDSX) host at the Canaccord Conference?
